FR2809619B1 - Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention - Google Patents

Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention

Info

Publication number
FR2809619B1
FR2809619B1 FR0007231A FR0007231A FR2809619B1 FR 2809619 B1 FR2809619 B1 FR 2809619B1 FR 0007231 A FR0007231 A FR 0007231A FR 0007231 A FR0007231 A FR 0007231A FR 2809619 B1 FR2809619 B1 FR 2809619B1
Authority
FR
France
Prior art keywords
oxidation
obtaining
active ingredients
aqueous formulations
sensitive active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0007231A
Other languages
English (en)
Other versions
FR2809619A1 (fr
Inventor
Francois Dietlin
Daniele Fredj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMATOP
Original Assignee
PHARMATOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8851012&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2809619(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PHARMATOP filed Critical PHARMATOP
Priority to FR0007231A priority Critical patent/FR2809619B1/fr
Priority to MXPA03000001A priority patent/MXPA03000001A/es
Priority to CA2415403A priority patent/CA2415403C/fr
Priority to US10/332,060 priority patent/US6992218B2/en
Priority to AU2001266120A priority patent/AU2001266120A1/en
Priority to DZ013384A priority patent/DZ3384A1/fr
Priority to CNA018136702A priority patent/CN1556694A/zh
Priority to CZ200313A priority patent/CZ200313A3/cs
Priority to NZ523458A priority patent/NZ523458A/en
Priority to RU2003100090/15A priority patent/RU2003100090A/ru
Priority to YU103A priority patent/YU103A/sh
Priority to APAP/P/2002/002711A priority patent/AP1880A/en
Priority to PCT/FR2001/001749 priority patent/WO2001093830A1/fr
Priority to PE2001000715A priority patent/PE20030508A1/es
Priority to TW090118576A priority patent/TWI237570B/zh
Publication of FR2809619A1 publication Critical patent/FR2809619A1/fr
Priority to MA26990A priority patent/MA26926A1/fr
Publication of FR2809619B1 publication Critical patent/FR2809619B1/fr
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D19/00—Degasification of liquids
    • B01D19/0005—Degasification of liquids with one or more auxiliary substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Removal Of Specific Substances (AREA)
FR0007231A 2000-06-06 2000-06-06 Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention Expired - Lifetime FR2809619B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0007231A FR2809619B1 (fr) 2000-06-06 2000-06-06 Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
NZ523458A NZ523458A (en) 2000-06-06 2001-06-06 New method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
YU103A YU103A (sh) 2000-06-06 2001-06-06 Postupak za dobijanje vodenih formulacija sa aktivnim sastojcima koji su osetljivi na oksidaciju
US10/332,060 US6992218B2 (en) 2000-06-06 2001-06-06 Method for obtaining aqueous formulations of oxidation-sensitive active principles
AU2001266120A AU2001266120A1 (en) 2000-06-06 2001-06-06 Method for obtaining aqueous formulations of oxidation-sensitive active principles
DZ013384A DZ3384A1 (fr) 2000-06-06 2001-06-06 Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation
CNA018136702A CN1556694A (zh) 2000-06-06 2001-06-06 对氧化作用敏感的活性组分水溶液制剂的制备方法
CZ200313A CZ200313A3 (cs) 2000-06-06 2001-06-06 Způsob získávání vodných prostředků z aktivní látky citlivé k oxidaci
MXPA03000001A MXPA03000001A (es) 2000-06-06 2001-06-06 Nuevo metodo para obtener formulaciones acuosas con principios activos susceptibles a oxidacion y las soluciones acuosas obtenidas de este modo.
RU2003100090/15A RU2003100090A (ru) 2000-06-06 2001-06-06 Способ получения водных композиций действующих начал, чувствительных к окислению
CA2415403A CA2415403C (fr) 2000-06-06 2001-06-06 Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation
APAP/P/2002/002711A AP1880A (en) 2000-06-06 2001-06-06 Method for obtaining aqueous formulations of oxidation sensitive active principles.
PCT/FR2001/001749 WO2001093830A1 (fr) 2000-06-06 2001-06-06 Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation
PE2001000715A PE20030508A1 (es) 2000-06-06 2001-07-16 Un proceso nuevo para obtener formulaciones acuosas de principios activos sensibles a la oxidacion y las soluciones asi obtenidas
TW090118576A TWI237570B (en) 2000-06-06 2001-07-31 New method for obtaining aqueous formulations with active principles susceptible to oxidation and the aqueous solutions thus obtained
MA26990A MA26926A1 (fr) 2000-06-06 2003-01-03 Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0007231A FR2809619B1 (fr) 2000-06-06 2000-06-06 Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention

Publications (2)

Publication Number Publication Date
FR2809619A1 FR2809619A1 (fr) 2001-12-07
FR2809619B1 true FR2809619B1 (fr) 2004-09-24

Family

ID=8851012

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0007231A Expired - Lifetime FR2809619B1 (fr) 2000-06-06 2000-06-06 Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention

Country Status (16)

Country Link
US (1) US6992218B2 (fr)
CN (1) CN1556694A (fr)
AP (1) AP1880A (fr)
AU (1) AU2001266120A1 (fr)
CA (1) CA2415403C (fr)
CZ (1) CZ200313A3 (fr)
DZ (1) DZ3384A1 (fr)
FR (1) FR2809619B1 (fr)
MA (1) MA26926A1 (fr)
MX (1) MXPA03000001A (fr)
NZ (1) NZ523458A (fr)
PE (1) PE20030508A1 (fr)
RU (1) RU2003100090A (fr)
TW (1) TWI237570B (fr)
WO (1) WO2001093830A1 (fr)
YU (1) YU103A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
FR2832063B1 (fr) * 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
FR2851164B1 (fr) * 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
WO2006086744A1 (fr) 2005-02-09 2006-08-17 Macusight, Inc. Formulations pour un traitement oculaire
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
US20070077303A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
FR2894154B1 (fr) * 2005-12-06 2008-03-14 Pharmatop Scr Nouveau procede de stabilisation de substances minerales ou organiques sensibles a l'oxydation.
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
RU2419421C2 (ru) * 2006-07-18 2011-05-27 Хенфарма Лабораторио С.Л. Инъецируемая жидкая композиция парацетамола
EP1992334A1 (fr) * 2007-05-08 2008-11-19 Docpharma NV/SA Formule stable pour le stockage de médicament phénolique sensible à l'oxydation, spécialement le paracétamol, et qui comprend une solution de médicament aqueuse désoxygénée par le processus de fabrication à température contrôlée de la formule
DE102007026975A1 (de) * 2007-06-01 2008-12-04 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Antioxidationsmittel für Lebensmittel
EP2170313A2 (fr) * 2007-06-18 2010-04-07 Combino Pharm, S.L. Préparations aqueuses d'acétaminophène pour injection
WO2009081283A2 (fr) * 2007-06-18 2009-07-02 Combino Pharm, S.L. Formulations aqueuses d'acétaminophène pour injection
WO2009064928A1 (fr) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Acétaminophène par voie intraveineuse en dose réduite
EP2307056B1 (fr) * 2008-01-17 2021-12-15 Pharmis Biofarmacêutica, LDA Compositions pharmaceutiques aqueuses stables contenant du paracetamol
FR2926992B1 (fr) * 2008-02-06 2011-01-14 Moly Pharma Formulation d'une solution de paracetamol injectable,procede de preparation et de conditionnement d'une telle solution et dispositif de conditionnement d'une telle solution
US20110097470A1 (en) * 2008-06-11 2011-04-28 Joerg Kowalczyk Highly active antioxidant based on trehalulose
EP2243477A1 (fr) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracétamol destiné à l'administration parentérale
EP2464332B1 (fr) 2009-08-13 2016-03-02 Neogen N.V. Formulation de paracétamol en solution aqueuse stable en stockage
US8404748B2 (en) * 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
AU2009353168B2 (en) * 2009-09-24 2014-09-04 Kabushiki Kaisha Toshiba Carbon dioxide gas absorbent solution
US20120245230A1 (en) 2009-12-10 2012-09-27 Tecnimede-Sociedade Tecnico- Medicinal, S.A. Method and composition for preparing stable liquid formulations of paracetamol
US20110207824A1 (en) * 2010-02-25 2011-08-25 Moly Pharma Formulation of an injectable paracetamol solution, method for preparing and packaging such a solution and device for packaging such a solution
JP2014505081A (ja) * 2011-02-10 2014-02-27 ネオジャン，エヌ．ヴェー． 貯蔵安定性のある水溶液中のパラセタモール配合物
US20130022670A1 (en) 2011-03-04 2013-01-24 Gruenenthal Gmbh Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration
ES2414557B1 (es) * 2012-01-16 2014-06-10 Novocat Farma, S.A. Composición acuosa de paracetamol para inyección
ITMI20121154A1 (it) 2012-06-29 2013-12-30 Sint Sa Soluzione iniettabile di acetaminofene per la somministrazione spinale
CN103006550A (zh) * 2012-12-11 2013-04-03 哈药集团三精制药股份有限公司 一种胞磷胆碱钠注射液及其制备方法
US20140303254A1 (en) * 2013-04-08 2014-10-09 InnoPharma Licensing LLC Process Of Manufacturing A Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation
UY35988A (es) * 2014-02-27 2015-09-30 Sint Sa Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
BR102014005885B1 (pt) 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
WO2016008546A1 (fr) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Formulation aqueuse comprenant du paracétamol et de l'ibuprofène
CN104288099B (zh) * 2014-09-25 2017-02-15 西安仁仁药业有限公司 一种布洛芬注射液的制备方法
JP6923447B2 (ja) 2015-03-27 2021-08-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与のための安定な製剤
EP3701944B1 (fr) 2015-06-18 2021-12-08 Estetra SRL Unité posologique orodispersible contenant un composant d'estétrol
NO3106148T3 (fr) 2015-06-18 2018-08-11
EP3120837A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
BR112018014354A2 (pt) 2016-02-05 2018-12-18 Innopharma Inc processo de fabricação de uma bolsa de infusão estável, pronta para uso para uma formulação sensível à oxidação
BR112019005439A2 (pt) 2016-09-23 2019-06-18 Gruenenthal Gmbh formulação estável para administração parenteral de tapentadol
WO2018140894A1 (fr) 2017-01-30 2018-08-02 Nevakar, Inc Compositions de norépinéphrine et procédés associés
WO2018192664A1 (fr) * 2017-04-20 2018-10-25 Hyloris Developments Sa Procédé de préparation d'une composition à faible teneur en oxygène dissous, comprenant de l'acétaminophène, et éventuellement un ou plusieurs ains, et une composition obtenue à partir de celui-ci
WO2019150381A1 (fr) * 2018-02-01 2019-08-08 Joshi Mahendra R Composition pharmaceutique stable et procédé de production d'une injection de chlorhydrate d'isoprotérénol
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
MX2020012233A (es) 2018-05-16 2021-01-29 Bayer Healthcare Llc Formula de suspension de alta concentracion para medicamentos en capsula de gel blanda para resfriado y gripe.
WO2020074419A1 (fr) * 2018-10-08 2020-04-16 Merz Pharma Gmbh & Co. Kgaa Flacon pré-rempli de neurotoxine
US10478453B1 (en) 2019-01-15 2019-11-19 Exela Pharma Sciences, LLC Stable, highly pure L-cysteine compositions for injection and methods of use
CN113105040A (zh) * 2021-04-02 2021-07-13 武汉工控工业技术研究院有限公司 一种自然水体无菌处理及长期保存技术
CN116803376B (zh) * 2023-08-04 2024-02-13 广州白云山星群(药业)股份有限公司 一种复方愈创木酚磺酸钾口服溶液的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3443004A (en) * 1965-04-08 1969-05-06 Ciba Geigy Corp Injectable solution containing 6-chloroor 6-trifluoromethyl-7-sulfamyl - 1,2,4-benzothiodiazine-1,1-dioxide diuretic
DD153578A1 (de) * 1980-10-22 1982-01-20 Hans Meffert Stabilisierung von oxydationsempfindlichen wirkstoffen,vorrangig dithranol in arzneizubereitungen
RO93391B (ro) * 1984-12-20 1988-03-31 Eli Lilly And Company Procedeu pentru prepararea unor saruri de dobutamina
CA2126093A1 (fr) * 1992-10-21 1994-04-28 Owen Gan Composition d'irrigation des tissus intra-oculaires et de maintien de la mydriase pendant la chirurgie intra-oculaire
AU5680994A (en) * 1992-12-10 1994-07-04 Abbott Laboratories Stabilized catecholamine solutions
FR2740338B1 (fr) * 1995-12-01 1997-12-05 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees contenant de la dobutamine
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention

Also Published As

Publication number Publication date
CA2415403C (fr) 2011-05-24
CZ200313A3 (cs) 2003-11-12
FR2809619A1 (fr) 2001-12-07
DZ3384A1 (fr) 2001-12-13
US20040054012A1 (en) 2004-03-18
PE20030508A1 (es) 2003-06-25
WO2001093830A1 (fr) 2001-12-13
TWI237570B (en) 2005-08-11
US6992218B2 (en) 2006-01-31
MA26926A1 (fr) 2004-12-20
AP1880A (en) 2008-08-19
YU103A (sh) 2006-05-25
AP2002002711A0 (en) 2002-12-31
CN1556694A (zh) 2004-12-22
RU2003100090A (ru) 2004-05-10
NZ523458A (en) 2005-08-26
MXPA03000001A (es) 2004-03-19
CA2415403A1 (fr) 2001-12-13
AU2001266120A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
FR2809619B1 (fr) Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
FR2814380B1 (fr) Poudre de microcapsules et procede d'obtention
FR14C0080I2 (fr) Methode d'administration d'un anticorps
PT1242425E (pt) Compostos de n-(5,7-dimetoxi¬1,2,4|triazolo1,5-a|pirimidin-2-il) arilsulfonamida e sua utilizacao como herbicidas
AU2001256947A1 (en) Formulations for neutralization of chemical and biological toxants
NO20025450D0 (no) Ny farmasöytisk sammensetning
DZ2420A1 (fr) Formulations nouvelles comprenant l'amoxycilline et du clavulanate et procédé pour leur préparation.
FR2822826B1 (fr) Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
HUP0301763A3 (en) Process to prepare aqueous formulations of pesticides
HUP0204563A3 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
FR2766708B1 (fr) Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
ITBO20000446A0 (it) Unita' e metodo di trasferimento di spezzoni di sigaretta .
HUP0204285A3 (en) Pharmaceutical composition containing 6-hydroxi-8-{4-[4-(2-pyrimidinyl)piperazinyl]-butyl}-8-azaspiro[4.5]-7.9-dione and improved process alleviation of anxiety
HUP0302310A3 (en) Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone and process for their preparation
HUP0302291A3 (en) Sulfonamide derivatives, process for their preparation and their use for preparation of pharmaceutical compositions
FR2779346B1 (fr) Procede d'obtention d'un principe actif anti-radicalaire et photoprotecteur, principe actif obtenu, composition cosmetique
FR2822846B1 (fr) Procede de preparation et de selection d'anticorps
FR2829927B1 (fr) Nouvelles compositions cosmetiques et leur procede d'obtention
AU2002322424A8 (en) Novel methods and formulations for administration of active agents
FR2792532B1 (fr) Nouvelles compositions antiseptiques et leur procede d'obtention
PL357466A1 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them
IL140127A0 (en) Process for the preparation of optically active 1,4-benzodixoane-2-carboxylic acid and derivatives thereof
IT1276684B1 (it) Formulazioni idrosolubili di collagenasi stabilizzata e procedimento per la loro preparazione
IL141607A0 (en) Microbial process for preparation of optically active 3-hydroxypyrolidine derivatives

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20